Brief: Qlife Signs Collaboration Agreement With Hipro Biotechnology
Dec 4 (Reuters) - Qlife Holding AB QLIFE.ST :
* QLIFE SIGNS COLLABORATION AGREEMENT WITH HIPRO
BIOTECHNOLOGY
* AGREMENT INCLUDES DISTRIBUTION AND SALES OF EGOO HEALTH TO
CHINESE HOSPITALS
* HIPRO IS FORECASTING INTO MILLIONS OF EGOO TESTS SOLD
DURING
FIRST FULL YEAR EXPECTED TO BE 2025
Source text for Eikon: ID:nWkrbMkDcy
Further company coverage: QLIFE.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Qlife Holding AB
See all newsAdvisory: Alerts on Qlife's agreement with global pharma company withdrawn
Brief: Qlife Holding Enters Feasibility Deal With Pharma Co For Egoo Health Biomarker
Brief: Qlife Holding Q1 EBITDA Loss SEK 5.5 Mln
Sweden's Qlife Q1 revenue drops, losses widen slightly
Brief: Qlife Holding Q4 EBITDA At SEK -1.6 Million